Evidence for daptomycin Etest lot-related MIC elevations for Staphylococcus aureus

Diagnostic Microbiology and Infectious Disease

Volumn 65, Issue 3, 2009, Pages 306-311

  Friedrich, Lawrence ^a   Thorne, Grace ^a   Steenbergen, Judith N ^a   Anastasiou, Diane ^a   Koeth, Laura ^b  

^a CUBIST PHARMACEUTICALS INC   (United States)

^b Laboratory Specialists Inc   (United States)

Author keywords

Daptomycin; MRSA; Susceptibility testing

Indexed keywords

AGAR; CALCIUM; DAPTOMYCIN;

ARTICLE; BACTERIUM ISOLATE; BROTH DILUTION; CONTROLLED STUDY; EPSILOMETER TEST; MEASUREMENT ERROR; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; DAPTOMYCIN; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 71749117298     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2009.07.012     Document Type: Article

References (34)

1. Andrew J., Wale M., Wale L., and Greenwood D. The effect of cultural conditions on the activity of LY146032 against staphylococci and streptococci. J. Antimicrob. Chemother. 20 (1987) 213-221
2. Bolstrom A., Engelhardt A., Karlsson A., Ho P., Mills K., Wanger A., and Howe R. Validation of a novel daptomycin gradient with calcium against the CLSI reference using FDA 510(k) review criteria for susceptibility devices. 105th General Meeting of the American Society for Microbiology; June 5-9; Atlanta, Georgia (2005) (Abstract #C-317)
3. Bolstrom A., Engelhardt A., Karlsson A., Ho P., Mills K., Wanger A., and Howe R. Comparison of MIC methods for daptomycin, agar dilution, and novel Etest + calcium using Mueller Hinton and isosensitest agar versus CLSI broth microdilution. 105th General Meeting of the American Society for Microbiology; June 5-9; Atlanta, Georgia (2005) (Abstract #C-318)
4. Castanheira M., Jones R., and Safer H. Update of the in vitro activity of daptomycin tested against 6710 Gram-positive cocci isolated in North America (2007). Diagn. Microbiol. Infect. Dis. 61 (2008) 235-239
5. Center for Devices and Radiological Health. Class II special controls guidance document: antimicrobial susceptibility test (AST) systems; guidance for industry and FDA. March 5, 2007. Available at: (2007). http://www.fda.gov/downloads/medicaldevices/deviceregulationandguidancedocuments/UCM071462 Accessed July 6, 2009
6. Clinical and Laboratory Standards Institute (CLSI). Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard-seventh edition, M07-A7 (2008), Clinical and Laboratory Standards Institute, Wayne, PA
7. Clinical and Laboratory Standards Institute (CLSI). Development of in vitro susceptibility testing criteria and quality control parameters; approved standard-third edition, M23-A3 (2008), Clinical and Laboratory Standards Institute, Wayne, PA
8. Cotroneo N., Harris R., Perlmutter N., Beveridge T., and Silverman J. Daptomycin exerts bactericidal activity without lysis of Staphylococcus aureus. Antimicrob. Agents Chemother. 52 (2008) 2223-2225
9. Critchley I., Draghi D., Sahm D., Thornberry C., Jones M., and Karlowsky J. Activity of daptomycin against susceptible and multidrug-resistant Gram-positive pathogens collected in the SECURE study (Europe) during 2001-2001. J. Antimicrob. Chemother. 51 (2003) 639-649
10. Cubicin [package insert] (2008), Cubist Pharmaceuticals Inc, Lexington, MA
11. Engelhardt A., Yusof A., and Ho P. Influence of technical variables on Etest daptomycin (DPC) MIC testing of recent clinical MRSA. 48th Annual ICAAC/IDSA 46th Annual Meeting; October 25-28; Washington, DC (2008) (Abstract #D-2220)
12. Etest Customer Information Sheet 014. Etest Daptomycin® DPC-technical variables that may cause discrepancies in MIC testing. Available at:. http://abbiodisk.com/pdf/cis/M0000601.pdf Accessed April 2, 2009
13. Fuchs P., Barry A., and Brown S. Daptomycin susceptibility tests: interpretive criteria, quality control, and effect of calcium ions on in vitro tests. Diagn. Microbiol. Infect. Dis. 38 (2000) 51-58
14. Fuchs P., Barry A., and Brown S. Evaluation of daptomycin susceptibility testing by Etest and the effect of different batches of media. J. Antimicrob. Chemother. 48 (2001) 557-561
15. Fuchs P., Barry A., and Brown S. In vitro activity of daptomycin against staphylococci. J. Antimicrob. Chemother. 49 (2002) 467-470
16. Hsu D., Hidayat L., Hindler J., Karlsson A., Yusof A., and Wong-Beringer A. Comparison of method-specific vancomycin minimum inhibitory concentration values and their predictability for treatment outcome of methicillin-resistant Staphylococcus aureus (MRSA) infections. Int. J. Antimicrob. Agents 32 (2008) 378-385
17. Huang Y., Liao C., Teng L., and Hsueh P. Daptomycin susceptibility of unusual Gram-positive bacteria: comparison of results obtained by Etest and the broth microdilution method. Antimicrob. Agents Chemother. 51 (2007) 1570-1572
18. Jevitt L., Thorne G., Traczewski M., Jones R., McGowan J., Tenover F., and Brown S. Multicenter evaluation of the Etest and disk diffusion methods for differentiating daptomycin-susceptible from non-daptomycin-susceptible Staphylococcus aureus isolates. J. Clin. Microbiol. 44 (2006) 3098-3104
19. Jones R., and Barry A. Antimicrobial activity and spectrum of LY146032, a lipopeptide antibiotic, including susceptibility testing recommendations. Antimicrob. Agents Chemother. 31 (1987) 625-629
20. Jorgensen J., and Crawford S. Assessment of two commercial susceptibility test methods for determination of daptomycin MICs. Antimicrob. Agents Chemother. 44 (2006) 2126-2129
21. Koeth L., and DiFranco J. Comparison of daptomycin Etest MICs with broth microdilution MICs against a challenge set of 58 S. aureus and 44 Enterococcus spp. 45th Annual ICAAC Meeting; December 16-19; Washington, DC (2005) (Abstract #D-1641)
22. Koeth L., and DiFranco J. Comparison of daptomycin Etest MICs on European Mueller Hinton and isosensitest agars against 20 Staphylococcus aureus. 48th Annual ICAAC/IDSA 46th Annual Meeting; October 25-28; Washington, DC (2008) (Abstract #D-2221)
23. Koeth L., Leclercq R., and Olsson-Liljequist B. Comparison of daptomycin and vancomycin MIC results by DIN, NCCLS, SFM, and SRGA methods for 297 Gram-positive organisms. Int. J. Antimicrob. Agents 23 (2004) 17-24
24. Lamp K., Rybak K., Bailey E., and Kaatz G. In vitro pharmacodynamic effects of concentration, pH, and growth phase on serum bactericidal activities of daptomycin and vancomycin. Antimicrob. Agents Chemother. 36 (1992) 2709-2714
25. LaPlante K., and Rybak M. Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model. Antimicrob. Agents Chemother. 48 (2004) 4665-4672
26. Pfaller M., Sader H., and Jones R. Evaluation of the in vitro activity of daptomycin against 19615 clinical isolates from Gram-positive cocci collected in North America hospitals (2002-2005). Diagn. Microbiol. Infect. Dis. 57 (2007) 459-465
27. Pillar C., Draghi D., Dowzicky M., and Sahm D. In vitro activity of tigecycline against Gram-positive and Gram-negative pathogens as evaluated by broth microdilution and Etest. Antimicrob. Agents Chemother. 46 (2008) 2862-2867
28. Prakash V., Lewis J., and Jorgensen J. Vancomycin MICs for methicillin-resistant Staphylococcus aureus isolates differ based upon the susceptibility test method used. Antimicrob. Agents Chemother. 52 (2008) 4528
29. Rybak M., Hershberger E., Moldovan T., and Grucz. In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against staphylococci and enterococci, including vancomycin-intermediate and -resistant strains. Antimicrob. Agents Chemother. 44 (2000) 1062-1066
30. Sader H., Streit J., Fritche T., and Jones R. Antimicrobial activity of daptomycin against multidrug resistant Gram-positive strains collected worldwide. Diagn. Microbiol. Infect. Dis. 50 (2004) 201-204
31. Sader H., Fritsche T., and Jones R. Daptomycin bactericidal activity and correlation between disk and broth microdilution method results in testing Staphylococcus aureus strains with decreased susceptibility to vancomycin. Antimicrob. Agents Chemother. 50 (2006) 2330-2336
32. Sader H., Rhomberg P., and Jones R. Nine-hospital study comparing broth microdilution and Etest method results for vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 53 (2008) 3162-3165
33. Silverman J., Perlmutter N., and Shapiro H. Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus. Antimicrob. Agents Chemother. 47 (2003) 2538-2544
34. Wootton M., MacGowan A., and Walsh T. Comparative bactericidal activities of daptomycin and vancomycin against glycopeptides-intermediate Staphylococcus aureus (GISA) and heterogenous GISA isolates. Antimicrob. Agents Chemother. 50 (2006) 4195-4197